Interventional, Randomised controlled trial (interventional), Randomized
Recruiting
NSW, QLD, VIC
Secondary progressive MS
This is a Phase 3 clinical trial. Its aim is to demonstrate the efficacy and safety of an investigational drug compared to placebo in participants with Secondary Progressive MS. Globally, approximately 868 participants will be randomly assigned to the investigational drug or placebo. This is a double-blind study. This means the study doctor and participant will not know if they are receiving the investigational drug or placebo. Participants will receive an intravenous infusion once a month (every 4 weeks). The study is expected to last between 2.5 and 4.5 years.
The above information is not intended to contain all considerations relevant to a patient’s potential participation in a clinical trial.
Already started
NSW:
Royal North Shore Hospital
Principal Investigator: John Parratt
Site contact is Celia Miller NSLHD-MSClinicalTrials@health.nsw.gov.au
QLD:
Princess Alexandra Hospital
Principal Investigator: Stefan Blum
Site contact is Genevieve Skinner genevieve.skinner@health.qld.gov.au
VIC:
Austin Health
Principal Investigator: Marion Simpson
Site contact is Melanie McMurtrie ncress@austin.org.au or +61 03 9496 3705
NSW, VIC, QLD
Yes
4/12/2024
"*" indicates required fields